Pseudomonas aeruginosa (P. aeruginosa) is a zoonotic pathogen that can infect a variety of animals, including poultry. However, as there is no commercial vaccine available it is imperative that new and effective vaccines are developed. In this study, 2 monovalent DNA vaccines (pOPRL and pOPRF), one divalent combination DNA vaccine (pOPRL+pOPRF) and one fusion DNA vaccine (pOPRLF) were constructed based on the oprL and oprF genes of P. aeruginosa. These vaccines were administered to chickens, an outer membrane protein vaccine (OMP vaccine) and inactivated vaccine used as positive controls. The serum antibody, interferon-γ (IFN-γ), interleukin-2 (IL-2) and interleukin-4 (IL-4) concentrations were determined and lymphocyte proliferation assays were performed. After challenging with virulent P. aeruginosa, protective efficacy was evaluated. Following vaccination, serum antibodies, stimulation index (SI) values, concentrations of IL-2 and IFN-γ in chickens vaccinated with the bivalent combination DNA vaccine and fusion DNA vaccine were found to be significantly higher than in those chickens vaccinated with the 2 monovalent DNA vaccines. Moreover, the immune indexes in the bivalent combination DNA vaccine group were higher than those in the fusion DNA vaccine group. However, the concentrations of IL-4 in the 4 DNA vaccine groups were of no significant difference. The protective efficacy rate provided by pOPRL, pOPRF, pOPRLF, pOPRL+pOPRF, inactivated vaccine and OMP vaccine were 53.3%, 40%, 66.7%, 80%, 93.3%, and 80%, respectively. The results indicate that DNA vaccines constructed with the oprL and oprF genes of P. aeruginosa, particularly the divalent combination DNA vaccine, represent better potential vaccines. This study has laid a foundation for the design and application of future DNA vaccines of P. aeruginosa.
INTRODUCTION
Pseudomonas aeruginosa (P. aeruginosa) is a zoonotic pathogenic bacteria that can cause pneumonia and cystic fibrosis in humans (Talwalkar and Murray, 2016; Chen et al., 2018) , as well as animal hemorrhagic pneumonia and septicemia (Mohamed, 2004; Gu et al., 2016) . It has caused tremendous harm to human health and difficulties in the development of animal husbandry. In China, with the rapid development of intensive animal farming, the incidence of P. aeruginosa infection in poultry has increased significantly. The pathogen is able to infect chickens, turkeys, pigeons, cockroaches, ducks, and other poultry. In chickens, P. aeruginosa infection is often secondary to other diseases and can present as a mixed infection with other pathogens such as Escherichia coli and Salmonella. A major control measure of this disease includes drug treatment, particularly treatment with antibiotics. Unfortunately, P. aeruginosa is significantly resistant to multiple classes of antibacterial agents, such as carbapenems, and the rate of resistance increases rapidly (Lister et al., 2009; Trinh et al., 2017; Shariati et al., 2018) . This drug resistance has led to fewer effective antibiotics to choose from and the difficulty of treatment is worsening. Thus, it is necessary to seek a new strategy for the prevention and control of this disease.
Vaccination is one new effective strategy. Currently, available vaccines to prevent infectious disease in poultry include attenuated vaccines, inactivated vaccines, live viral, or bacterial vectors vaccines (Witter and Hunt, 1994) . Although there are some reports on the study of P. aeruginosa vaccines, no commercialized vaccines can yet be used clinically (Rashid et al., 2017) . Hence, there is an urgency to develop P. aeruginosa vaccines. The new generation vaccines against pathogenic microorganisms include the recombinant subunit vaccine, gene-deleted live vaccine, and DNA vaccines. Among these, DNA vaccines have become a topic of interest in the field of vaccine research because of their advantages, which include ease of preparation and low cost (Golshani et al., 2015) . Furthermore, the induction of potent cellular responses often gives DNA vaccination an immunological advantage over subunit protein vaccination (Corr et al., 1996; Gurunathan et al., 2000; Smooker et al., 2004; Gong et al., 2013) . Thus, DNA vaccines are known as the third revolution in the history of vaccine development.
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The selection of protective antigen genes is a key factor affecting the immune efficacy of DNA vaccines. The immunogen genes currently available for research on novel vaccines include the outer membrane protein (OMP) gene, flagellin gene, and toxin gene, etc. The OMP, encoded by the oprL gene, oprF gene, oprI gene, and so on, is one of the major protective antigens of P. aeruginosa. There are some reports on the research of recombinant subunit vaccines and DNA vaccines based on the oprF and oprI genes. A study by Gomi et al. (2017) showed that the DNA vaccine of the oprF gene, prepared with the AdC7 vector, could be used to treat the respiratory infection caused by P. aeruginosa. Saha et al. (2006) constructed the fusion DNA vaccine of the oprF and oprI genes and detected immune efficacy after co-immunizing mice with the P. aeruginosa pcrV and pilA DNA vaccine. Yu et al. (2016) prepared the fusion DNA vaccine with the oprF gene of P. aeruginosa and the VP22 gene of herpes simplex virus and evaluated the immune effect. The study of Gao et al. (2017) showed that the recombinant subunit vaccine construct based on the oprL gene could effectively induce a Th17 response in vaccinated animals. However, only minimal research on a DNA vaccine based on the oprL gene of P. aeruginosa has been performed.
In this study, we used 2 protective antigen genes, oprL and oprF of P. aeruginosa, as the basis for construction of the monovalent, divalent combination and gene fusion DNA vaccines. OprL and oprF genes are part of the genes encoding the OMP of P. aeruginosa. Therefore, the immune response and protective efficacy in chickens vaccinated with these DNA vaccines were detected with the OMP vaccine and an inactivated vaccine as control. The goal of this study was to lay the foundation for the development of DNA vaccines against the P. aeruginosa infection of chickens.
MATERIALS AND METHODS

Bacterial Strains and Chickens
A commercially available chicken P. aeruginosa strain (CAU0792) was used for this study (China Institute of Veterinary Drug Control, IVDC). Healthy 1-d old broilers were purchased from the Animal Center Laboratory of Henan province, China, and were kept and handled using procedures consistent with regulations for experimental animals in China. The study protocol was approved by the Animal Monitoring Committee of Henan University of Science and Technology (Permit Number 2017-0032; 27 March 2017) .
Amplification of Target Genes
Primers were designed according to the nucleotide sequences of the oprL and oprF genes of P. aeruginosa (GenBank accession number AE004091.2) and primer sequences are listed in Table 1 . Genomic DNA of the P. aeruginosa CAU0792 strain was extracted using a conventional cetyltriethyl ammnonium bromide method (Zhang et al., 2010) . The target gene fragments were amplified using genomic DNA as a template. The oprL gene was amplified using primer pairs 1&2 and 3&4, resulting in fragment I (containing the initiation and termination codons) and fragment II (which only contained the initiation codon). The oprF gene was amplified using primer pairs 5&6 and 7&8, resulting in fragment III (containing the initiation and termination codons) and fragment IV (which only contained the termination codon). Amplified products were purified using a gel extraction mini kit (Shanghai Watson Biological Engineering Company, Shanghai, China) and sequenced.
Construction of Recombinant Plasmids
Purified gene fragments I and III were digested with BamHI/EcoRI (TaKaRa, Dalian, Liaoning, China) and ligated into eukaryotic expression vector pcDNA3.1(+) (Invitrogen, San Diego, CA, USA), resulting in 2 recombinant plasmids. Competent E. coli DH5α was transformed with the 2 recombinant plasmids. Ampicillinresistant colonies were then grown in Luria-Bertani medium containing 50 μg/mL ampicillin at 37
• C with shaking. The plasmids were extracted and identified using restriction enzymes. The positive plasmids were named pcDNA-OPRL (pOPRL) and pcDNA-OPRF (pOPRF). Gene fragment II was cloned into the BamHI/EcoRI site of pcDNA3.1(+), followed by the insertion of fragment IV into EcoRI/XhoI, resulting in the recombinant plasmid pcDNA-OPRL-OPRF (pOPRLF). The 3 plasmids were prepared on a large scale using the alkaline lysis method and the plasmid preparations were adjusted to 1 μg/μL using phosphate-buffered saline (PBS, 0.01 M, pH 7.2) for subsequent experiments.
Extraction of Outer Membrane Proteins of P. Aeruginosa
After growth in nutrient broth medium for 24 h, the P. aeruginosa culture was centrifuged at 2,000 g for 5 min. The pellet was then washed twice and resuspended with 20 mM Tris-HCl (pH 7.4). The bacteria were lysed by ultrasonication and centrifuged at 3,000 g for 10 min. The supernatant was removed and centrifuged for 2 h at 100,000 g at 4
• C. The pellet was then dissolved in 2% sodium lauroyl sarcosine solution and incubated at 37
• C for 30 min. The sample was centrifuged for 1 h at 100,000 g at 4
• C and the pellet, namely the OMP of P. aeruginosa, was obtained. The concentration of OMP was determined using the Bradford method.
Preparation of Oil-emulsion Inactivated Vaccine and OMP Vaccine
The concentration of the P. aeruginosa suspension was adjusted to 2 × 10 10 CFU/mL with sterile saline and inactivated with formaldehyde. Tween-80 (6% of the total volume) was added to the inactivated bacteria liquid and thoroughly mixed to an aqueous phase. The oil phase consisted of 94% white oil, 6% span-80, and 2% aluminum stearate. The aqueous phase and the oil phase were mixed in a ratio of 1: 2 to yield the P. aeruginosa inactivated vaccine. The oil-emulsion OMP vaccine was prepared as described above. The concentration of antigen in the oil-emulsion OMP vaccine was 1 μg/μL.
Vaccination Protocol
Prior to vaccination, healthy 1-d old chickens (n = 120) were reared in a purpose-built animal house with controlled environmental light, temperature, and humidity. All chickens had ad libitum access to water and to non-medicated feed. General health monitoring was performed on all chickens from the day of arrival until the completion of this study. Chickens were assigned to 8 groups (n = 15 chickens/group), following a period of adaptation to the new feeding environment.
Vaccination was performed at 2 wk of age by intramuscular (IM) injection. The injection site was prepared with 2% iodine and 70% alcohol (alcohol was used to remove the iodine and then the alcohol was allowed to evaporate) and vaccines were administered using sterile 1 mL syringes. Chickens in the 2 monovalent DNA vaccine (pOPRL and pOPRF) groups, fusion DNA vaccine (pOPRLF) group, and the empty vector (pCDNA3.1(+)) group were injected with 200 μL of recombinant plasmid pOPRL solution, pOPRF solution, pOPRLF solution, and empty vector pcDNA3.1(+) solution, respectively, with each containing 200 μg of DNA. Chickens in the bivalent combination DNA vaccine group (pOPRL+pOPRF) received 100 μg of each of the vaccine constructs. Chickens in the inactivated vaccine and OMP vaccine groups were vaccinated with 200 μL of oil-emulsion inactivated vaccine and OMP vaccine of P. aeruginosa, respectively. Chickens in the control group were given 200 μL sterile normal saline by intramuscular injection. All chickens were vaccinated 3 times at 2-wk intervals. Following each vaccination, chickens were closely observed for any adverse reactions. Any chickens that presented as depressed, lacking appetite or that showed other clinical signs of illness, were isolated to a quiet feeding environment and fed more palatable feed until they recovered.
Detection of Serum Antibody
Following the first vaccination, blood samples (5 samples per group) were collected from the wing veins weekly for 6 wk prior to challenge. After wing veins were disinfected with iodine and alcohol, blood samples were collected using 1 mL sterile syringes. Sera were then tested for antibodies using an indirect ELISA with 10 9 CFU/mL of P. aeruginosa suspension and the OMP of P. aeruginosa as a coating antigen. Rabbit anti-chicken IgG-horseradish peroxidase (SigmaAldrich, St. Louis, MO, USA) was used as a secondary antibody. In brief, microtiter plates (eBioscience, San Diego, CA, USA) (96-well) were coated with 50 μL of the OMP (10 mg/mL) or P. aeruginosa suspension (10 9 CFU/mL) and blocked with 5% bovine serum albumin (Sigma, St. Louis, USA). Subsequently, 1:100 diluted serum samples were added to the plates and incubated at 37
• C for 1.5 h, followed by 3 washes with phosphate buffered saline containing Tween 20. The secondary antibody was then added and incubated at 37
• C for 1.5 h. After washing, ortho-phenylene diamine (Sigma, St. Louis, USA) was added and the reaction allowed to proceed for 10 min. Enzyme activity was stopped with 2 M H 2 SO 4 and the A value was measured at 492 nm.
Lymphocyte Proliferation Assay
Two weeks following each vaccination, blood samples were collected from vaccinated chickens (5 samples per group). Lymphocytes were then separated from the peripheral blood and the concentration adjusted to 2 × 10 7 cells/mL. A volume of 50 μL of cell suspension was seeded into a 96-well culture plate (Greiner Bio-One, Longwood, Germany) and each experiment was repeated 3 times. Each well was pulsed with 50 μL of 20 μg/mL P. aeruginosa OMP (experimental well) or a 50 μL culture medium (negative control). The plates were incubated at 37
• C under 5% CO 2 for 72 h, followed by the addition of 10 μL 5 mg/mL 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide and cultured for 3 h. After centrifugation for 10 min, the supernatant was discarded and 150 μL of dimethyl sulfoxide was added. The plate was then incubated for 10 min until all crystals had dissolved. The A value of each well was measured at 570 nm. Stimulation index (SI) values were estimated using the following equation: SI = A (experimental well)/A (negative control well).
Cytokine Test
Two weeks following each vaccination, peripheral blood lymphocytes, activated by the OMP of P. aeruginosa, were prepared as described above. The cells were cultured at 37
• C under 5% CO 2 for 72 h and the supernatants harvested. Interleukin-2 (IL-2), interleukin-4 (IL-4), and interferon-γ (IFN-γ) concentrations in the supernatants were detected using a commercial ELISA kit (Yuan Ye Biotech Company, Shanghai, China) according to the manufacturer's instructions.
Challenge Experiment
Two weeks after the third vaccination, all chickens were challenged with the virulent P. aeruginosa strain CAU0792 (5LD50/one chicken) by intramuscular injection. After this challenge, chickens were reared for a further 2 wk. Chickens were closely observed every day for clinical signs of illness post-challenge. Chickens showing signs of depression and/or lack of appetite were isolated and placed under observation. Chickens that were anorexic or dyspneic, and those with hemorrhagic diarrhea or other abnormal gastro-intestinal signs were withdrawn from the experiment and euthanized by intravenous injection of pentobarbital sodium. Survival time and survival number of each group were calculated.
Statistical Analysis
Statistical analyses were conducted using SAS software (Version 9.4; SAS Institute). Analysis of variance was used to determine significant differences in means between the experimental groups. Differences with P < 0.05 were considered significant.
RESULTS
Identification of Recombinant Plasmids
The oprL and oprF genes were inserted into pcDNA3.1(+) to construct the recombinant plasmids. The plasmids were extracted and digested with restriction enzymes and the products were then analyzed by agarose gel electrophoresis. As shown in Figure 1 , the target DNA fragments of 517 bp, 1063 bp, and 1570 bp were obtained, indicating that the DNA vaccines were constructed successfully.
Results of Serum Antibody Detection
Sera collected 1 to 6 wk after the first vaccination were assayed for the presence of specific antibodies by indirect ELISA. Serum antibodies in the 4 DNA vaccine groups, inactivated vaccine group, and OMP vaccine group increased following vaccination (Figure 2) . However, antibody concentrations in the pcDNA3.1(+) group and normal saline group remained low and there were no significant differences observed between them. Following the first vaccination, no differences in antibodies between the 4 DNA vaccine groups, inactivated vaccine group, and OMP vaccine group were recorded. From the second vaccination, antibodies detected in the pOPRL+pOPRF group, pOPRLF group, inactivated vaccine group, and OMP vaccine group were higher than those detected in the pOPRL group and pOPRF group (P < 0.05). Four weeks after the first vaccination, antibodies detected in the bivalent combination DNA vaccine group were higher than those detected in the fusion DNA vaccine group (P < 0.05). No significant differences in antibody levels among the pOPRL+pOPRF group, inactivated vaccine group, and OMP vaccine groups were observed, regardless of whether the coating antigen was the OMP of P. aeruginosa or the P. aeruginosa suspension. Furthermore, the antibodies detected in the inactivated vaccine group and the OMP vaccine group were not significantly different, although the antibody concentrations in the inactivated vaccine group were slightly higher than those in the OMP vaccine group when the P. aeruginosa suspension was the coating antigen (Figure 2A) . On the contrary, the latter was slightly higher than the former when the coating antigen was the OMP of P. aeruginosa ( Figure 2B ).
Lymphocyte Proliferation Assay
To investigate the cellular immune response induced by the DNA vaccines, the proliferation of the peripheral blood lymphocytes at 3 time points following vaccination was assessed, and the results are shown in Figure 3 . After each vaccination, the SI values for the 4 DNA vaccine groups, inactivated vaccine group and OMP vaccine group were consistently higher than the values obtained for the empty vector and normal saline groups (P < 0.05). Following the first vaccination, no difference among DNA vaccine groups, inactivated vaccine group, and OMP vaccine group was detected. After the second vaccination, the SI values in the pOPRL+pOPRF group, pOPRLF group, inactivated vaccine group, and OMP vaccine group were significantly higher than those in the pOPRL and pOPRF groups (P < 0.05). Following the third vaccination, the SI values in the inactivated vaccine group, OMP vaccine group, and bivalent combination DNA vaccine groups were significantly higher than those in the fusion DNA vaccine group (P < 0.05).
Cytokine Assay Results
IL-2, IL-4, and IFN-γ concentrations in vaccinated chickens were determined after each vaccination. The concentrations of the 3 cytokines in each of the vaccine groups were always higher than those of the empty vector group and normal saline group after vaccination. Following the first vaccination, no significant differences were observed in the concentrations of the 3 cytokines among the 4 DNA vaccine groups, OMP vaccine group, and inactivated vaccine group. After the second and third vaccinations, the concentrations of IL-2 and IFN-γ detected in the pOPRL+pOPRF group and pOPRLF group were higher than those in the pOPRL, pOPRF, OMP vaccine, and inactivated vaccine groups (P < 0.05). After the third vaccination, the concentrations of IL-2 and IFN-γ detected in the pOPRL+pOPRF group were higher than those in the pOPRLF group (P < 0.05). However, no significant differences in the concentrations of IL-4 among the 2 monovalent DNA vaccine groups, bivalent combination DNA vaccine group, fusion DNA vaccine group, OMP vaccine group, and inactivated vaccine group were observed ( Figures 4A-C) .
Challenge Study
Groups of chickens were challenged with live virulent P. aeruginosa 2 wk following the last vaccination. The number of surviving chickens was counted every day until day 14 post-challenge. Chickens in the pcDNA3.1(+) group and normal saline group began to die from the second day after the challenge onwards ( Figure 5) . None of the chickens in the 2 control groups survived more than 5 d after the challenge. Chickens in the pOPRL and pOPRF groups began to die on the 3rd day, and up until 14 d after the challenge, the survival numbers in the pOPRL and pOPRF groups were 8 and 6, respectively. Chickens died on the 4th day in the pOPRLF group, pOPRL+pOPRF group, OMP vaccine group, and inactivated vaccine group. The number of surviving chickens in the pOPRLF group, pOPRL+pOPRF group, and OMP vaccine group remained unchanged from the 7th, 6th, and 6th day, respectively. Only 1 chicken died (on the 4th day) from the inactivated vaccine group. The protective rates of DNA vaccines pOPRL, pOPRF, pOPRLF, pOPRL+pOPRF, inactivated vaccine, and OMP vaccine were found to be 53.3%, 40%, 66.7%, 80%, 93.3%, and 80%, respectively.
DISCUSSION
P. aeruginosa is a typical zoonotic pathogen which can not only infect humans, but also chickens, mink and sheep. With an increase in drug resistance of the pathogen, prevention through immunization is particularly important. As no commercial vaccine against this disease currently exists, vaccine research has become an area of interest in this field. Some research has focused on potential vaccines against P. aeruginosa, including traditional vaccines, such as attenuated live vaccine and inactivated vaccine, and the new generation vaccines, such as the recombinant subunit vaccine, DNA vaccine and conjugate vaccine (Price et al., 2002; Staczek et al., 2003; Zuercher et al., 2006; Döring and Pier, 2008; Mousavi et al., 2016) . In this study, we constructed monovalent, fusion and divalent combination DNA vaccines based on the oprL and oprF gene of P. aeruginosa and detected the immune efficacy of these DNA vaccines. The ELISA results showed that the antibodies induced by the fusion and divalent combination DNA vaccines, especially the latter, were higher than the 2 monovalent DNA vaccines. Although the fusion DNA vaccine contains only 1 recombinant plasmid, pOPRLF, 2 antigen genes are present in the recombinant plasmid. Vaccinated chickens were able to produce antibodies against the 2 antigens. However, the monovalent DNA vaccine could only induce chickens to produce antibodies against 1 antigen following vaccination. This may be the reason why antibodies induced by pOPRLF were higher than pOPRF and pOPRL. After vaccination with the OMP vaccine, chickens mostly produced antibodies against the OMP of P. aeruginosa. However, it was found that chickens vaccinated with the inactivated vaccine produced antibodies against a variety of P. aeruginosa antigens. This may explain why slightly higher antibody concentrations were detected in the OMP vaccine group than in the inactivated vaccine group when the OMP was used as a coating antigen, and vice versa. Regardless, the antibodies induced by the divalent combination DNA vaccine were comparable to that of the OMP vaccine and inactivated vaccine, suggesting that the divalent combination DNA vaccine induced a relatively strong humoral immune response.
Similar to the humoral immune response, the cellular immune response also plays an important role during the process of anti-infective immunity. DNA vaccines can induce effective cellular immune responses. In this study, we detected the ability of lymphocytes to proliferate and measured cytokine levels after vaccination with DNA vaccines to evaluate the cellular immune response. The level of lymphocyte proliferation stimulated with ConA is frequently used to evaluate the cell immune response (Chen et al., 2015; Chi et al., 2017) . However, the level of immune cell proliferation induced by ConA, which is a nonspecific stimulator, is easily influenced by environmental factors. Based on this, instead of using ConA we adopted the OMP of P. aeruginosa as the stimulator. All of the DNA vaccines used in this study could induce the proliferation of peripheral blood lymphocytes. In particular, the ability of the divalent combination DNA vaccine to induce lymphocyte proliferation was higher than for the other DNA vaccines and similar to that of the OMP vaccine and inactivated vaccine.
Th cells are involved both in the cellular immune response and the humoral immune response. The detection of Th1 and Th2 cytokines can reflect cellular and humoral immune responses to some degree (Van Damme et al., 2001) . In this study, all vaccines, including the OMP vaccine, inactivated vaccine, and the 4 DNA vaccines, induced high concentrations of Th1 cytokines IL-2, IFN-γ, and Th2 cytokine IL-4 in peripheral blood lymphocytes from vaccinated chickens. Concentrations of IL-2 and IFN-γ that were measured for the divalent combination DNA vaccine exceeded those recorded for other vaccines. However, the IL-4 concentrations for the divalent combination DNA vaccine were not better than for other vaccines. Thus, it can be seen that the DNA vaccines constructed in this study, particularly the divalent combination DNA vaccine, could induce a predominantly Th1 response. The challenge experiment in this study demonstrated that the divalent combination DNA vaccine could provide a better protective efficiency than other DNA vaccines, because the number of surviving chickens in the divalent combination DNA vaccine group was numerically higher than that for other DNA vaccines, although differences between groups were not verified statistically. This indicates that the DNA vaccines constructed in this study play an anti-infection role mainly by enhancing the Th1 immune response. However, the molecular mechanism needs to be studied further. The levels of immune response and protective rate in vaccinated chickens induced by the divalent combination DNA vaccine were higher than for the fusion DNA vaccine. This may be because the oprL and oprF genes were ligated into the EcoRI restriction site instead of a linker DNA sequence. Hence, the expression of the protein by pOPRLF may have resulted in mutual interference between the 2 domains (OprL and OprF). Specifically, some T cell epitopes and B cell epitopes may have been covered. As such, it can be expected that changing the way in which these two genes were fused may improve the immune efficacy of the fusion DNA vaccine.
CONCLUSIONS
Four DNA vaccines, including 2 monovalent DNA vaccines, a fusion DNA vaccine, and a divalent combination DNA vaccine based on the oprL gene and oprF gene against avian P. aeruginosa, were successfully constructed. All of the DNA vaccines in this study were able to induce a certain humoral immune response and cellular immune response, accompanied by a protective effect. Among the DNA vaccines studied, the divalent combination DNA vaccine (pOPRL+pOPRF) showed the most promise and may provide a valuable reference for the design of future DNA vaccines for P. aeruginosa.
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